Ra Capital Management, L.P. Buys 548,580 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 548,580 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $7.91 per share, with a total value of $4,339,267.80. Following the completion of the acquisition, the director owned 16,231,717 shares of the company’s stock, valued at approximately $128,392,881.47. The trade was a 3.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $6.91 per share, with a total value of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Up 6.7%

Shares of ARTV stock opened at $8.54 on Friday. Artiva Biotherapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $14.53. The firm has a market cap of $211.11 million, a PE ratio of -2.41 and a beta of 2.38. The stock has a 50 day moving average of $8.93 and a 200-day moving average of $6.14.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ARTV. Bank of America Corp DE raised its stake in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares in the last quarter. Prelude Capital Management LLC acquired a new position in Artiva Biotherapeutics during the third quarter worth $41,000. Dimensional Fund Advisors LP acquired a new position in Artiva Biotherapeutics during the first quarter worth $131,000. OMERS ADMINISTRATION Corp acquired a new position in Artiva Biotherapeutics during the fourth quarter worth $91,000. Finally, Sanctuary Advisors LLC acquired a new position in Artiva Biotherapeutics during the first quarter worth $139,000.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. HC Wainwright upped their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Finally, Wedbush upped their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.